A wide variety of cell types have been generated from mouse embryonic stem cells (ESCs) and human ESCs (hESCs), including blood cells, neurons, and heart cells ([@bib19]; [@bib3]; [@bib14]; [@bib30]). This has opened up exciting prospects for the use of hESCs in regenerative medicine. However, two major limiting factors need to be addressed before pluripotent stem cell--based therapies can come to fruition. Although hESCs express low levels of major histocompatibility class (MHC) molecules, MHC expression increases with differentiation. Thus, differentiated progeny of hESCs may express MHC levels sufficient to cause rejection in genetically mismatched patients receiving hESC-derived cells. This issue may be addressed by the discovery of induced pluripotent stem (iPS) cells, which can be generated from somatic cells by de novo expression of four "reprogramming" transcription factors: Oct4, Klf4, Sox2, and c-Myc ([@bib25]). Because it appears that essentially all somatic cell types tested thus far can be reprogrammed into iPS cells ([@bib8]; [@bib23]), iPS cells can be generated from individual patients, thereby avoiding the use of allogeneic cell sources for therapy.

However, because all ESCs and iPS cells are inherently tumorigenic and form teratomas in vivo, regardless of the reprogramming method (e.g., integration-free, small molecule, etc.), differentiated cell cultures intended for cell replacement therapy must be completely free of contamination with residual pluripotent cells. One of the ways in which pluripotent cells can be eliminated is by cell irradiation; however, this method is only suitable for red blood cells and platelets, which are enucleated and thus resistant to irradiation. For all other cell derivatives, alternative strategies have to be used, such as the introduction of suicide genes that ablate remaining iPS cells or the pharmacological inhibition of antiapoptotic genes specifically expressed in pluripotent, but not differentiated, ESCs ([@bib20]; [@bib1]).

It is noteworthy that despite intensive efforts, in vitro differentiation of pluripotent stem cells into tissues of interest remains challenging, and that only a fraction of the several hundred specialized cell types in the human body have been generated. The most successful model for ESC differentiation is the hematopoietic system. To date, most mature cell types, including erythrocytes, monocytes, natural killer cells, B and T lymphocytes, and platelets have been differentiated from ESCs in vitro. Nevertheless, with the exception of erythrocytes, the process is either too inefficient for clinical use and/or the differentiated cells do not exhibit full functionality ([@bib14]). In this issue of the *Journal of Experimental Medicine*, Takayama et al. describe a novel iPS-based approach to produce fully functional human platelets that could be useful in the clinic.

Generation of platelets in vitro
================================

Platelet transfusions reduce the risk of severe bleeding in a wide range of patients and are a commonly practiced clinical procedure ([@bib29]). However, platelet transfusions are costly and may lead to immune system complications such as sepsis ([@bib13]), underlining a real need for alternative platelet therapies. Platelets are the progeny of megakaryocytes, a rare population of hyperploid cells that reside in the adult bone marrow, and are generated by the extension of pro-platelet--like filopodia into the vasculature; these extensions shed thousands of cell fragments into the circulation under the shear force of blood flow ([@bib21]; [@bib9]). The formation of megakaryocytes and platelets requires specific transcription factors, including GATA-1, NF-E2, and SCL, which also play key roles in erythropoiesis ([@bib22]; [@bib15]). In addition, megakaryocyte numbers, maturation, and pro-platelet formation are dependent on thrombopoietin (TPO; [@bib10]; [@bib6])

Using mouse ESCs, several groups managed to produce platelets and/or megakaryocytes in vitro ([@bib4]; [@bib5]; [@bib11]). The generation of mature megakaryocytes from hESCs was first reported by [@bib6]. The hESCs were differentiated on OP9, a bone marrow stromal cell line derived from mice lacking macrophage colony-stimulating factor ([@bib17]), which has been widely used to support differentiation of both mouse ESCs and hESCs into hematopoietic cells in vitro. The ESC-derived megakaryocytes obtained after 15--17 d of co-culture supplemented with TPO expressed specific surface antigens, including the lineage markers CD41a (integrin αIIb or GPIIb) and CD42b (GPIbα). However, platelets were not detected ([@bib6]). More recently, [@bib26] improved upon the protocol of [@bib6] by co-culturing ESCs on either OP9 or C3H10T1/2 stroma for an initial period of 14--15 d with vascular endothelial growth factor (VEGF). This led to the formation of so-called ES-sacs, which are sac-like structures consisting of a morphologically distinct outer layer of cells with endothelial-like properties. ESC sacs also contain a robust population of round hematopoietic-like cells expressing shared markers of blood and endothelium, such as VE-cadherin and CD31, as well as the hematopoietic cell-specific markers CD34, CD41a, and CD45 ([@bib26]). These hematopoietic cells have the capacity to form hematopoietic colonies in vitro, suggesting that ESC sacs serve as an endothelial-type niche for early blood cell progenitors. When cultured for 24 d in medium that was first supplemented with VEGF and then with TPO plus other cytokines (interleukin \[IL\]-6, IL-11, and stem cell factor \[SCF\]), the hematopoietic progenitors from ESC sacs formed megakaryocytes. In addition, megakaryocytes obtained in this manner released platelets that expressed CD41a and CD61 (integrin β3 or GPIIIa) and could be activated in response to ADP and thrombin. However, hESC-derived megakaryocytes contained fewer granules and yielded far fewer platelets than their normal counterparts (2--3 compared with ∼1,000-3,000 per megakaryocyte; [@bib24]; [@bib26]). In addition, the in vivo functionality of the ES sac--derived platelets was not demonstrated.

[@bib26] now report the generation of hiPS cell--derived megakaryocytes and platelets with in vivo functionality. The main difference between this study and their previous work is the use of hiPS cells derived from human dermal fibroblasts instead of hESCs. In brief, hiPS cells were co-cultured on C3H10T1/2 feeder cells in the presence of VEGF for 14--15 d, and the resulting hiPS sacs were replated in the presence of human TPO and other cytokines (IL-6, IL-11, and SCF) for an additional 8--12 d to form megakaryocytes ([Fig. 1](#fig1){ref-type="fig"}). The platelet yield per megakaryocyte under these conditions was improved by approximately two- to threefold compared with their previous study ([@bib26]). The hiPS-derived platelets were detectable in the circulation for at least 24 h after transfusion into irradiated NOD-SCID-*Il2rg*^−/−^ mice. Importantly, intravital microscopy revealed that upon laser-induced vessel injury, the transfused platelets participated in the formation of blood clots, showing for the first time the formation of functional platelets from pluripotent human cells in an in vivo assay.

![**The generation of human platelets from hiPS cells and the role of c-MYC.** iPS cells are generated by the reprogramming of human dermal fibroblasts (HDFs) with the transcription factors OCT4, KLF4, SOX2, and c-MYC (OKSM). In hiPS cells, exogenous c-MYC levels are initially high and activate expression of endogenous c-MYC. Exogenous c-MYC expression subsequently decreases. Co-culture with stromal cells in the presence of VEGF drives formation of an iPS sac containing hematopoietic progenitors. Further culture in megakaryocyte (Mk) conditions (TPO, SCF, and heparin) reactivates exogenous c-MYC expression, leading to the differentiation of megakaryocytes. Down-regulation of exogenous c-MYC expression leads to the efficient production of platelets, whereas sustained exogenous c-MYC expression inhibits platelet generation. Platelets obtained with this protocol, when transferred into mice, can participate in thrombus formation after vessel injury.](JEM_20102428R_RGB_Fig1){#fig1}

Role of c-MYC in iPS and platelet generation
============================================

[@bib26] also provide insight into the role of c-MYC in the formation of megakaryocytes and platelets. Previous work using transgenic mice overexpressing c-Myc under the control of the platelet-specific promoter PF4 showed a small but significant increase in the number of low ploidy megakaryocytes and a reduction in platelet numbers ([@bib28]). In support of this observation, c-Myc expression is up-regulated by TPO in megakaryocytes ([@bib2]). Paradoxically, two recent studies reported that the inactivation of c-Myc, either by ablation of the gene, or more indirectly by deletion of the c-Myc regulator RBM15, likewise leads to a cell autonomous increase in the number of low ploidy megakaryocytes ([@bib7]; [@bib18]). The reasons for this apparent discrepancy are not clear, but could be explained or by the assumption that c-Myc has both positive and negative targets that modulate megakaryopoiesis, and that these targets are regulated in a manner sensitive to different transcription factor concentrations.

The first hint about a role of c-MYC in the process of platelet generation from hiPS cells came from the finding that hiPS clones generated with all four reprogramming transcription factors yielded larger numbers of megakaryocytes than hiPS cells generated with only three factors (SOX2, OCT4, and KLF4) in the absence of c-MYC. Further analyses revealed that the four-factor clones reactivated expression of exogenous c-MYC (as well as the other reprogramming factors) at the megakaryocyte stage and that the clone that yielded the largest numbers of platelets showed a decrease of total (exogenous plus endogenous) c-MYC expression after day 15. This suggested that although c-MYC is beneficial for megakaryocyte formation, its sustained expression inhibits platelet formation ([Fig. 1](#fig1){ref-type="fig"}), a hypothesis that is supported by two lines of experiments. First, overexpression of c-MYC, but not of OCT4, SOX2, or KLF4, in ESCs led to an increase in megakaryocyte formation. Megakaryocytes generated by c-MYC overexpression exhibited impaired pro-platelet formation, lower ploidy, and a differentiation block and reduced levels of the platelet adhesion molecule GP1bα. Second, hiPS cells expressing an inducible form of c-MYC together with OCT4, KLF4, and SOX2 using a nonintegrating vector (Sendai virus) efficiently generated platelets when c-MYC was inactivated at day 22, but not when c-MYC expression was extended to day 26. It is also noteworthy that overexpression of c-MYC in ESCs to levels that are inhibitory for platelet formation activate the expression of the senescence-inducing *p14* (*ARF*) and *p16* (*INK4A*) genes. *p14* (*ARF*) and *p16* (*INK4A*) expression was not activated in the iPS clone that transiently expressed c-MYC and showed the highest platelet production efficiency. This indicates that a narrow window of c-MYC expression is required for efficient platelet development. Which, if any, of the observed effects of sustained c-MYC expression is the cause of the observed inhibition of platelet formation remains to be determined.

Thus, optimal platelet formation from patient-derived somatic cells requires two waves of c-MYC expression; the first contributes to the efficient reprogramming of somatic cells into hiPS cells (together with the other reprogramming factors) and the second mediates ES/iPS sac and megakaryocyte formation ([Fig. 1](#fig1){ref-type="fig"}). However, c-MYC expression has to be shut off to permit efficient platelet formation. In line with this interpretation is the finding that distinct threshold levels of c-Myc govern its output in vivo. Although low levels of deregulated c-Myc are sufficient to induce oncogenesis and ectopic proliferation of somatic cells, activation of the apoptotic and ARF/p53 intrinsic tumor surveillance pathways requires high c-Myc expression ([@bib16]).

No matter what roles c-Myc plays in the formation of megakaryocyte and platelets, the new work represents a step closer to the use of a highly desired cell type derived from iPS cells for cell replacement therapies. This prospect is all the more exciting because platelets are enucleated cells that can be irradiated, thereby eliminating safety concerns caused by the presence of contaminating iPS cells with the potential to cause tumors.
